Cargando…

The role of biomarker in later-line treatment for metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Kawakami, Takeshi, Yamazaki, Kentaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186531/ https://www.ncbi.nlm.nih.gov/pubmed/37201084 http://dx.doi.org/10.21037/jgo-2023-01

Ejemplares similares

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Finding a New Prognostic Biomarker for Metastatic Colorectal Cancer
por: Kim, Hungdai
Publicado: (2012)

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
por: Kawai, Sadayuki, et al.
Publicado: (2021)

Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2021)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
por: Xue, Wen-Hui, et al.
Publicado: (2023)

Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting
por: Riedl, Jakob Michael, et al.
Publicado: (2017)

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
por: Kawakami, Takeshi, et al.
Publicado: (2022)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
por: Denda, Tadamichi, et al.
Publicado: (2019)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study
por: Yuki, Satoshi, et al.
Publicado: (2023)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
por: Hamaguchi, Tetsuya, et al.
Publicado: (2019)

Biomarkers in colorectal cancer screening
por: Schab, Katarzyna, et al.
Publicado: (2017)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study
por: Conde, Elisa, et al.
Publicado: (2021)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Microbiota: An Emerging Biomarker in Colorectal Cancer
por: Tsiaoussis, John, et al.
Publicado: (2021)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

Non-invasive actionable biomarkers for metastatic prostate cancer
por: Luo, Jun
Publicado: (2016)

LINE-1 methylation shows little intra-patient heterogeneity in primary and synchronous metastatic colorectal cancer
por: Matsunoki, Aika, et al.
Publicado: (2012)

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice
por: Yang, Mengyuan, et al.
Publicado: (2023)

Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers
por: Gherman, Alexandra, et al.
Publicado: (2020)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Implication of Different Tumor Biomarkers in Drug Resistance and Invasiveness in Primary and Metastatic Colorectal Cancer Cell Lines
por: Sánchez-Díez, Marta, et al.
Publicado: (2022)

Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis
por: Karani, Amanda, et al.
Publicado: (2020)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
por: Miyo, Masaaki, et al.
Publicado: (2020)

Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
por: Tanaka, Akira, et al.
Publicado: (2018)

Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
por: Garajová, Ingrid, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mnab3uub0ckjj2ka8qqbti657n